Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.43 |
| ▸ | HRH2 | P25021 | 4/20 | 0.43 |
| ▸ | HRH1 | P35367 | 4/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025525 | 0.90 | HRH2 (0.49) | GNAI3GNAO1GNAI1HRH3HRH2 | |
| SCHEMBL10025514 | 0.90 | HRH2 (0.49) | GNAI3GNAO1GNAI1HRH3HRH2 | |
| SCHEMBL10192108 | 0.84 | HRH3 (0.51) | HRH3HRH2HRH1MAOBSIGMAR1 | |
| SCHEMBL26972452 | 0.82 | HRH3 (0.40) | HRH3MAOB | |
| SCHEMBL19709043 | 0.81 | HRH3 (0.43) | HRH3HRH2HRH1MAOB | |
| SCHEMBL21743256 | 0.81 | HRH3 (0.43) | HRH3HRH2HRH1MAOB | |
| SCHEMBL19709379 | 0.81 | HRH3 (0.43) | HRH3HRH2HRH1MAOB | |
| SCHEMBL8116676 | 0.79 | GNAI3 (0.56) | GNAI3GNAO1GNAI1HRH3HRH2 | |
| SCHEMBL6176615 | 0.79 | GNAI3 (0.56) | GNAI3GNAO1GNAI1HRH3HRH2 | |
| SCHEMBL21667849 | 0.79 | HRH3 (0.45) | HRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | GNAI3 841/4885GNAO1 903/4885GNAI1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.